目标产品概况以及新型加密球菌病治疗方法的发现和开发路径
David B Meya1, Manu De Rycker2, Ian H Gilbert2
1Department of Internal Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
The Journal of infection
|November 1, 2025
概括
由于全球高死亡率和治疗限制,开发了一种针对新型抗密码球菌剂的目标产品概况 (TPP). 该TPP旨在指导创建更安全,更有效的加密球菌疾病治疗方法.
科学领域:
- 菌类学 菌类学是指菌类学.
- 传染性疾病 传染性疾病
- 药物开发 药物开发
背景情况:
- 新型菌 (Cryptococcus neoformans) 和菌 (Cryptococcus gattii) 是全球重要的健康威胁,特别影响低收入和中等收入国家的艾滋病毒感染者.
- 目前针对加密球菌病的治疗方法存在局限性,导致全球高发病率和死亡率.
研究的目的:
- 为新型抗密码球菌药物建立一个目标产品概况 (TPP).
- 引导发现和开发新的治疗方法,以解决加密球菌疾病管理中的未满足需求.
主要方法:
- 根据临床和微生物学的要求,定义了新的抗密码球菌剂的关键属性.
- 概述了为实现TPP提出的发现和开发途径.
主要成果:
- 该TPP强调了改善的安全性,优越或与现有治疗方法可比的活性,以及跨患者群体和疾病谱的广泛适用性.
- 关键属性包括适合所有年龄组,多种配方 (口服/静脉注射),可接受的疗法,最小的药物相互作用,热稳定性和高阻抗障碍.
结论:
- 开发的TPP为参与创建下一代抗密码球菌疗法的利益相关者提供了一个关键的框架.
- 该倡议旨在加快开发更有效的治疗方法来对抗加密球菌脑膜炎和肺炎,降低全球疾病负担.
更多相关视频
09:06Author Spotlight: Photodynamic Therapy as a Novel Approach to Induce Petite Colonies in Drug-Resistant Candida for Antifungal Research
Published on: March 29, 2024
1.1K
05:37Label-Free Quantitative Proteomics Workflow for Discovery-Driven Host-Pathogen Interactions
Published on: October 20, 2020
7.4K
相关概念视频
Drug Discovery: Overview
10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Preclinical Development: Overview
5.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.8K
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Cystic Fibrosis: Pathogenesis
698
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
698
Biopharmaceutical Factors Influencing Drug Product Design: Overview
227
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
227
Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K
